-- Winning project hopes to unlock invaluable insights on how
ECP could improve quality of life and clinical outcomes in chronic
lung allograft dysfunction --
DUBLIN, Nov. 16,
2022 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global
specialty pharmaceutical company, today announced the recipient of
2022's Advancing Extracorporeal Photopheresis (ECP)
Immunomodulation Investigator Award. Andrew
Fisher, the project's principal investigator won this year's
award for a project to help address significant unmet medical
need by evaluating responses to extracorporeal photopheresis
therapy (ECP) in chronic lung allograft dysfunction (CLAD).
The study hopes to identify potential novel biomarkers that
could guide a precision-medicine approach to ECP treatment, and
help people avoid the disability and mortality associated with CLAD
– a devastating complication that affects more than half of lung
transplant recipients within five years.
Lung transplantation is the only treatment offering a meaningful
improvement in survival and quality of life to selected patients
with life-threatening chronic lung disease. However, long-term
survival is significantly poorer than that in other organ
transplants, mainly due to the development of progressive immune
mediated damage to the lung allograft.
More than 50%1 of lung transplant recipients will
develop CLAD within five years. This can progress rapidly, leading
to lung function decline, respiratory failure, and death. As such,
there is an urgent need to identify new treatments that can arrest
the alloimmune mechanisms that drive CLAD as early as possible,
preserving longevity and quality of life while also reducing the
risk of repeat lung transplantation.
"There is an urgent need for treatments to stop CLAD early to
protect lung function, help preserve quality of life, and hopefully
prolong survival in lung transplant patients," said the
award-winning project's principal investigator, Andrew Fisher, Professor of Respiratory
Transplant Medicine at Newcastle University, and Honorary
Consultant Respiratory and Transplant Physician at The Newcastle
upon Tyne Hospitals NHS Foundation Trust's Institute of
Transplantation.
"The aim of the E-CLAD UK study is to see if adding a course of
ECP to current treatment is more effective at stabilizing the
function of transplanted lungs compared to standard treatments for
CLAD."
The winning project, 'Predicting Response to ECP in the
Treatment of CLAD after Lung Transplantation', is an in-depth
mechanistic evaluation of participants' immune responses. It is
hoped it will address a currently unmet clinical need and provide
powerful insights into how ECP treatment is working at
immunological level.
Professor Fisher was presented with the €50,000 prize at a
Therakos Institute-supported Workshop on Solid Organ
Transplantation and Extracorporeal Photopheresis in Monte Carlo, in September.
The award, now in its fifth year, is part of Mallinckrodt's ongoing commitment to the science of
immunomodulation through ECP across therapeutic applications. It
was designed to recognize individuals and institutions whose
innovative research contributes to the advancement of knowledge in
this broad area of medicine.
Entries were invited from clinicians and scientists working on
translational or outcomes-based research, as well as collaborative
projects. Submissions were assessed on a range of criteria,
including scientific merit, originality, and feasibility.
"Every year, the investigator award showcases the huge
array of cutting-edge, innovative, and ambitious research being
conducted in the use of ECP across a broad spectrum of disease
settings – and 2022 was no exception," said Steven Romano, M.D., Executive Vice President
and Chief Scientific Officer of Mallinckrodt. "As a pioneer in ECP
immunomodulation, Mallinckrodt is proud
to support those who continue to investigate this exciting field of
medicine. Congratulations to Professor Fisher and his team on
winning this extremely competitive award. We're looking forward to
seeing the results in the fullness of time."
The 2023 Advancing ECP Immunomodulation Investigator Award will
be open for entries during the first quarter of 2023
ABOUT THERAKOS
Mallinckrodt's Therakos therapeutic
platforms, including the latest generation
THERAKOS™ CELLEX™Photopheresis System, are used by academic
medical centres, hospitals, and treatment centres in more than 30
countries and have delivered more than 1 million treatments
globally. For more information, please
visit www.therakos.eu.
ABOUT MALLINCKRODT
Mallinckrodt is a global business
consisting of multiple wholly owned subsidiaries that develop,
manufacture, market and distribute specialty pharmaceutical
products and therapies. The Company's Specialty Brands reportable
segment's areas of focus include autoimmune and rare diseases in
specialty areas like neurology, rheumatology, hepatology,
nephrology, pulmonology, ophthalmology and oncology; immunotherapy
and neonatal respiratory critical care therapies; analgesics;
cultured skin substitutes and gastrointestinal products. Its
Specialty Generics reportable segment includes specialty generic
drugs and active pharmaceutical ingredients. To learn more about
Mallinckrodt, visit
https://www.mallinckrodt.com/.
Mallinckrodt uses its website as a
channel of distribution of important company information, such as
press releases, investor presentations and other financial
information. It also uses its website to expedite public access to
time-critical information regarding the Company in advance of or in
lieu of distributing a press release or a filing with the U.S.
Securities and Exchange Commission (SEC) disclosing the same
information. Therefore, investors should look to the Investor
Relations page of the website for important and time-critical
information. Visitors to the website can also register to receive
automatic e-mail and other notifications alerting them when new
information is made available on the Investor Relations page of the
website.
NOTES
1 Verleden G, Verleden S, Vos R.
Freedom from chronic lung allograft dysfunction (CLAD) or CLAD-free
survival: What's in a name? J Heart Lung Transplant
2019;38:1-2. doi: 10.1016/j.healun.2018.11.005.
CONTACTS
Investor Relations
Daniel Speciale
Global Corporate Controller and Chief Investor Relations
Officer
314-654-3638
daniel.speciale@mnk.com
Derek Belz
Vice President, Investor Relations
314-654-3950
derek.belz@mnk.com
Media
Michael Freitag / Aaron Palash / Aura
Reinhard
Joele Frank, Wilkinson Brimmer
Katcher
+1 212-355-4449
Mallinckrodt, the "M" brand mark and
the Mallinckrodt Pharmaceuticals logo are trademarks of a
Mallinckrodt company. Other brands are
trademarks of a Mallinckrodt company or
their respective owners. © 2022 Mallinckrodt Item code: EU-2200265.
Date of preparation: Nov. 2022
Logo -
https://mma.prnewswire.com/media/167103/mallinckrodt_plc_logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/mallinckrodt-announces-2022-advancing-extracorporeal-photopheresis-immunomodulation-investigator-award-301672286.html